Trials / Sponsors / Xcovery Holdings, Inc.
Xcovery Holdings, Inc.
Industry · 5 registered clinical trials — 1 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Non-small Cell Lung Carcinoma | Phase 1 / Phase 2 | 2026-07-01 |
| Completed | A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted Conditions Bioequivalency | Phase 1 | 2022-11-29 |
| Active Not Recruiting | eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Pa Non-small Cell Lung Cancer | Phase 3 | 2016-06-01 |
| Completed | Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer Advanced Solid Tumors, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | 2012-06-01 |
| Available | Expanded Access to Ensartinib for Participants With ALK+ NSCLC Non-Small Cell Lung Cancer, ALK Gene Rearrangement Positive | — | — |